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Secondary hyperparathyroidism causing increased jaw bone
density and mandibular pain: a case report
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We present the case of a 32-year-old male patient complaining of recurrent mandibular pain for 3.5 years. Panoramic radiog-
raphy indicated increased cortical density of the mandibular lower border. Scintigraphy and single-photon emission computed
tomography revealed metabolic hyperactivity in that region without pathologic lymph nodes. A bone biopsy specimen of the
mandibular lower border did not have inflammation or cytologic atypia. Endocrinologic investigation confirmed secondary hy-
perparathyroidism as a result of hypovitaminosis D. Several weeks after starting therapy with oral vitamin D supplements, the
symptoms completely disappeared. Increased cortical density is a rare manifestation of secondary hyperparathyroidism, which
normally causes the lamina dura to vanish and produces a ground-glass appearance as a result of blurring of the trabecular bone
pattern. Because focal hyperostosis can have multiple benign or malignant causes, radiologic examination of the jaw bones is
indispensable for evaluating orofacial pain. Increased cortical density may be caused by metabolic diseases, requiring further
investigations, including biopsy and blood analysis. (Oral Surg Oral Med Oral Pathol Oral Radiol 2017;■■:■■–■■)
Orofacial pain is a common complaint in the dental and
maxillofacial field. It can have a variety of causes, in-
cluding infection, benign and malignant neoplasia, and
metabolic diseases. Although orofacial pain mostly is due
to a local process, one should always rule out a system-
ic cause. This is especially true when no evident local
lesion can be found.
One such systemic cause may be endocrinologic in
origin—that is, hyperparathyroidism. The parathyroid
hormone (PTH) regulates serum calcium concentration
and bone metabolism. PTH level increases when the
serum calcium concentration is low, such as when calcium
intake is lacking or when very low vitamin D levels inhibit
sufficient enteral calcium uptake, and in the case of
chronic kidney disease.1,2
In general, PTH attempts to elevate serum calcium
levels by stimulating renal calcium reuptake, enteral
calcium uptake, and bony calcium release. The effects
of PTH can vary according to the age of the patient, the
serum PTH concentration pattern, and the skeletal site.
Persistently elevated PTH levels generally have cata-
bolic effects, whereas intermittent increases may be
anabolic.1
The bony alterations in hyperparathyroidism can also
involve the jaw bones. In general, the lamina dura van-
ishes and blurring of the trabecular bone pattern appears
as ground glass.2 Bicortical bony accumulation seems to
be less prevalent as an expression of metabolic bone
disease. We present a case in which secondary hyper-
parathyroidism caused bicortical mandibular expansion
and intermittent pain in the chin region. Several authors
have described cases of bone pain caused by
hyperparathyroidism.3,4 However, the radiographic image
mostly indicate bone demineralization, as in the case of
maxillofacial brown tumors. In our case bone pain pre-
sented with hyperostosis. We would like to raise attention
to this atypical oral manifestation of hyperparathyroid-
ism, because it should be included in the broad differential
diagnosis in patients with orofacial pain.
CASE REPORT
A 32-year old male patient presented with complaints of
recurrent chronic pain in the mandible, especially the chin
and submental region. The pain had a sudden onset,
without specific aggravating triggers, and it disap-
peared after several hours to days to recur a few weeks
later. This pattern was self-repeating over the preced-
ing 3.5 years. The dull pain did not radiate and wasn’t
neurogenic in origin, and it responded well to ibupro-
fen intake (600 mg 3 times a day). The latter was
prescribed by his general practitioner. The patient had
no other complaints. He did not suffer any allergies or
take any other medication. He had smoked for several
years. The dental and family histories were insignificant.
On clinical examination no abnormalities were found
(Figure 1). There was no intraoral evidence of patho-
logic conditions, but some enlarged lymph nodes were
palpable in the left and right submandibular regions. These
were nontender, soft, and mobile. There was no actual
clinical evidence of submental adenopathy, but an en-
larged submental node had been excised 1 year earlier.
The microscopic analysis revealed no pathologic
alterations.
To rule out a dental or periodontal cause, panoramic
radiography was performed. The cortical density of the
mandibular lower border was markedly increased,
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especially in the region between the mental foramen, as
well as in the maxillary canine region (Figure 2). The
patient had no complaints in the latter region. Cone beam
computed tomography (CT) confirmed the presence of
a thickened mandibular cortical layer (Figure 2).
At first sight, there was no obvious intraoral etiology
to explain the patient’s complaint or the hyperdense aspect
of the mandibular lower border. Therefore, skeletal bone
scintigraphy was performed. 99mTc-MDP scintigraphy
indicated increased tracer uptake in the anterior mandi-
ble and maxilla. Single-photon emission CT (SPECT),
which combines metabolic and anatomic information,
confirmed the osteoblastic hyperactivity in the mandi-
ble and ruled out any soft tissue involvement (Figure 3).
Although enlarged lymph nodes were palpable and vi-
sualized on CT, they did not have hyperactivity on SPECT.
The augmented metabolic activity can have several
causes. To rule out any benign (e.g., fibrous dysplasia)
or malignant neoplasm, a biopsy of the mandibular lower
border was performed in the region of greatest tracer
uptake. The specimen confirmed the increased density
of cortical bone without evidence of inflammation or cy-
tologic atypia (Figures 4 and 5).
Because the initial clinical and radiologic investiga-
tion raised the suspicion of a metabolic disease, a blood
analysis was performed. It revealed an increased level
of PTH (75.4 ng/L, normal range 14.9-56.9 ng/L) and de-
creased level of 25-OH-vitamin D (10.2 µg/L, normal
range 11.0-60.0 µg/L), as well as decreased serum calcium
and normal renal function. Liver tests and the serum phos-
phate level were normal. Therefore, the patient was
diagnosed with secondary hyperparathyroidism caused
by hypovitaminosis D. An oral vitamin D supplement (D-
Cure, cholecalciferol) was prescribed. As advised by our
colleagues of the department of endocrinology, the treat-
ment regimen consisted of 1 peroral ampulla (25,000 U/
mL) every 2 weeks during the first month, followed by
1 ampulla per month for the next 3 months. Six weeks
later, the patient reported a complete disappearance of
all complaints. The pain never recurred in the follow-
ing 6 months.
DISCUSSION
Hyperparathyroidism was first described by Von Reck-
linghausen in 1891, presenting its systemic effects.
Already in 1945, Weinmann5 reported the oral manifes-
tations of hyperparathyroidism in the mandible.
Hyperparathyroidism predominates in women, with a
general male:female ratio of 1:1.7. The average age of
patients with hyperparathyroidism is 34.02 years,6 but pa-
tients with secondary hyperparathyroidism may be slightly
younger.
PTH controls serum calcium levels by stimulating os-
teoclastic bone resorption. Excessive hormone release
leads to primary, secondary, or tertiary hyperparathy-
roidism depending on the etiology. Secondary reactive
hyperparathyroidism originates from a lack of serum
vitamin D and/or calcium, which can be caused by renal
failure, intestinal malabsorption, and/or lack of vitamin
D/calcium in the diet. It is typically caused by chronic
renal failure, mostly related to diabetes mellitus and
hypertension.
In secondary hyperparathyroidism, the serum level of
PTH is increased, together with hypocalcemia and
hyperphosphatemia, which differentiates it from primary
and tertiary hyperparathyroidism. Moreover, if alkaline
phosphatase is elevated, it indicates high bone turn-
over. The latter may also be present in Paget disease.7
Approximately 8%-16% of the worldwide population
suffers from a chronic kidney disease,8 and 4.3% of them
present with craniofacial brown tumors as a manifesta-
tion of hyperparathyroidism.9 The systemic symptoms of
hyperparathyroidism are described as “stones, bones,
groans, with psychiatric overtones.”6 In our patient, the
primary complaint was prolonged jaw pain without ev-
idence of chronic kidney disease. In a recent systematic
review, the incidence of oral pain in patients with hy-
perparathyroidism was 14.0%. However, the most common
reported symptom of hyperparathyroidism is facial asym-
metry or swelling (78.0%), followed by oral pain and
systemic symptoms (11.7%).6 Bone expansion can be
present with and without brown tumors.10 Other oral mani-
festations include neuropathy, postextraction complications,
periodontitis, and tooth mobility.6 Periodontitis may not
be caused by hyperparathyroidism but possibly be ex-
acerbated by it.10,11 A brown tumor is common in
hyperparathyroidism, especially in the mandible of female
patients with the primary form, though it is also found
in secondary, and more seldom in tertiary, hyperpara-
thyroidism. Cecchetti et al.9 reported a serum PTH level
>1000 pg/mL (normal range 10-55 pg/mL) in all pa-
tients with craniofacial brown tumors.
Occasionally, patients can present with a mandibular
fracture, as reported in a patient with primary
Fig. 1. Normal intraoral appearance.
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hyperparathyroidism.12 Giant cell epulis and Sagliker
syndrome are also possible manifestations. The mandi-
ble is more often affected than the maxilla, but bimaxillary
manifestation is common as well.6 In the present patient,
an excessive hypercorticalization of the mandibular
lower border was visualized on the panoramic radio-
graph and cone beam CT. Table I lists reported cases of
hyperparathyroidism causing facial pain. In contrast to
our patient, bony hypercorticalization wasn’t reported
in any of these cases.4,13-21 Because hypercorticalization
is not a typical oral manifestation of hyperparathyroid-
ism, extensive technical investigations to rule out other
etiologies were performed. The most common reported
radiologic feature of hyperparathyroidism is a loss of
the lamina dura in 7%-46% of cases.22-24 However, this
should not be considered a pathognomonic sign. Other
radiographic features that have been reported are a
decreased cortical thickness at the mandibular angle,25
cortical destruction, tooth displacement, root resorp-
tion, obliteration of the mandibular canal, and dystrophic
calcifications.6
A salt-and-pepper appearance of the skull can be found
on skull radiography, but it wasn’t performed in this
patient. Skeletal scintigraphy and positron emission to-
mography CT were ordered to rule out other foci of
metabolic hyperactivity, but lesions were found only in
the anterior mandible and, to a lesser extent, maxilla.
However, these imaging modalities cannot distinguish
among hyperparathyroidism, skeletal metastasis, oste-
itis fibrosa, Paget disease, and fibrous dysplasia,6,26,27 so
Fig. 2. Orthopantomogram and cone beam computed tomography revealed a dense mandibular lower border.
Fig. 3. Skeletal scintigraphy revealed increased tracer uptake in the mandibular chin region. Single-photon emission computed
tomography confirmed the bony etiology and ruled out any soft tissue involvement.
Fig. 4. A bony biopsy of the mandibular lower border was taken at the mental region.
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their main goal is to locate pathologic lesions to guide
further investigations.
There are several treatment modalities, depending on
the type of hyperparathyroidism. Parathyroidectomy
is the only definitive treatment for primary
hyperparathyroidism.28 For secondary hyperparathyroid-
ism, treatment involves reduction of the dietary
phosphorus intake and controlling PTH levels via
calcimimetics and vitamin D metabolites. Parathyroid-
ectomy is only performed if the pharmacotherapeutic
treatment fails.29 Tertiary hyperparathyroidism can be
treated by parathyroidectomy or with drugs such as
cinacalcet, with lower success rates for the latter.30 In the
present patient, the hypocalcemia, hyperparathyroid-
ism, and associated oral pain were successfully treated
with oral vitamin D and calcium supplementation. Oral
vitamin D substitution is reported as an effective treat-
ment for hypovitaminosis D. Moreover, it can decrease
the serum PTH level and restore it within normal
ranges.31,32 This is especially true when serum vitamin
D levels are low.32
As far as we know, there is no standard vitamin D
supplementation regime in patients with hypovitamino-
sis D–induced hyperparathyroidism and a normal renal
function. One should always take in account the serum
vitamin D level, renal function, and the patient’s gas-
trointestinal absorption (e.g., after bariatric surgery) when
prescribing vitamin D supplementation therapy.
Early detection is important to prevent long-term hy-
percalcemia and avoid deleterious cardiovascular and
skeletal effects,28 as found in hemodialysis patients with
serum calcium levels >10 mg/dL.29
CONCLUSION
Though it mostly causes bony demineralization, second-
ary hyperparathyroidism can also cause mandibular pain
and hypercorticalization. Mandibular hypercorticalization,
as revealed by radiologic investigation, is not a typical
manifestation of hyperparathyroidism.
Fig. 5. Biopsy specimen composed of dens cortical bone. The
bone is predominantly lamellar, partially woven, without further
abnormalities.
Table I. Case reports presenting hyperparathyroidism as a cause of pain
Author Primary complaint Pain Radiology Diagnosis HyperPTH type and cause
Masson et al.13 Mandibular swelling Yes Brown tumor Brown tumor Primary—carcinoma
Guney et al.14 Palatal swelling Yes Eroding mass Brown tumor Primary—adenoma
Chewing problems
Sutbeyaz et al.15 Palatal swelling Yes Cystic palatal mass Brown tumor Primary—adenoma
Mandibular swelling
Jafari-Pozve et al.4 Bony pain Yes Multiple radiolucencies Brown tumor Secondary—renal failure
Swelling of the cheeks
Vardhan et al.16 Maxillary swelling Yes Loss of lamina dura Giant cell lesion Primary—adenoma
Pain Ground-glass trabecular pattern
Maxillary radiolucency
Jakubowski et al.17 Mandibular edema Yes Unilocular radiolucency Brown tumor Secondary—renal failure
Pain Obliterated mandibular canal
Intra-oral nightly bleeding Displaced molars
Devresse et al.18 Painfull swelling of the Yes Osteolytic mandibular lesion Ossifying fibroma Secondary—renal failure
Mouth floor
Magalhães et al.19 Mandibular molar Yes Ground glass trabecular pattern Brown tumors Tertiary—renal transplant
Pain Osteolytic lesions
Nair et al.20 Mandibular swelling Yes Lytic lesion Brown tumor Secondary—vitamin D deficit
Outer cortex sclerosis
Verma et al.21 Pain Yes Loss of lamina dura Brown tumor Secondary—renal failure
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